Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Retained Earnings (2024 - 2025)

Caris Life Sciences has reported Retained Earnings over the past 2 years, most recently at -$2.5 billion for Q4 2025.

  • Quarterly results put Retained Earnings at -$2.5 billion for Q4 2025, down 3.09% from a year ago — trailing twelve months through Dec 2025 was -$2.5 billion (down 3.09% YoY), and the annual figure for FY2025 was -$2.5 billion, down 3.09%.
  • Retained Earnings for Q4 2025 was -$2.5 billion at Caris Life Sciences, up from -$2.6 billion in the prior quarter.
  • Over the last five years, Retained Earnings for CAI hit a ceiling of $669000.0 in Q2 2025 and a floor of -$2.6 billion in Q3 2025.